

Assessing response to treatment using imaging with PET/MRI in advanced renal cancer

Submission date 02/11/2016	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 16/11/2016	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 30/06/2026	Condition category Cancer	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-pet-mri-scans-for-people-with-kidney-cancer-that-has-spread-remap>

Contact information

Type(s)

Scientific

Contact name

Prof Vicky Goh

ORCID ID

<https://orcid.org/0000-0002-2321-8091>

Contact details

Division of Imaging Sciences & Biomedical Engineering, King's College London
Level 1, Lambeth wing
St. Thomas' Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH
+44 (0)207 188 5538
vicky.goh@kcl.ac.uk

Type(s)

Scientific

Contact name

Prof Gary Cook

Contact details

Division of Imaging Sciences & Biomedical Engineering, King's College London
Level 1, Lambeth wing
St. Thomas' Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH
+44 (0)207 188 5538
gary.cook@kcl.ac.uk

Additional identifiers**Protocol serial number**

31962

Study information**Scientific Title**

Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI): The REMAP study

Acronym

REMAP

Study objectives

PET/MRI improves response classification compared to routine CT imaging in metastatic renal cell carcinoma.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Southeast London Research Ethics Committee, 10/10/2016, ref: 16/LO/1499

Primary study design

Interventional

Study design

Randomised; Interventional; Design type: Diagnosis, Process of Care, Imaging

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Renal cell carcinoma

Interventions

Participants with metastatic renal cell cancer will undergo FDG PET/MRI scans at baseline, 12 and 24 weeks following the start of their standard treatment and results compared to the routine clinical CT scans at these time-points. Each PET/MRI will take approximately one hour. The imaging intervention is over 24 weeks and the imaging follow up period extends to the 36 week clinical CT scan. Subsequent consensus panel assessment of clinical and all imaging data up to 36-weeks will confirm disease status.

Intervention Type

Other

Primary outcome(s)

disease response or non-response measured by PET/MRI and CT at 12 and 24 weeks and clinical examination and CT at 36 weeks.

Key secondary outcome(s)

Time to progression will be measured by clinical examination and CT at standard three to six monthly follow up clinic visits.

Completion date

01/02/2023

Eligibility**Key inclusion criteria**

1. Adult patients (male or female > 18 years old) with metastatic renal cell carcinoma
2. Metastases with ≥ 1 measurable sites, ≥ 2 cm, planned for targeted therapy
3. ECOG performance status 0-2

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

120 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Contraindications to contrast-enhanced MRI or CT or FDG PET including renal impairment eGFR <50
2. Estimated prognosis < 12 weeks
3. ECOG performance status > 2
4. Previous radiotherapy

Date of first enrolment

01/12/2016

Date of final enrolment

31/07/2022

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**King's College London and Guy's and St Thomas' PET Centre**

Level 1, Lambeth wing

St. Thomas' Hospital

Guy's and St. Thomas' NHS foundation Trust

Westminster Bridge Road

London

England

SE1 7EH

Study participating centre**Mount Vernon Cancer Centre**

East and North Hertfordshire NHS trust

Mount Vernon Hospital

Rickmansworth Road

Northwood

England

HA6 2RN

Sponsor information**Organisation**

King's College London

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Professor Vicky Goh (vicky.goh@kl.ac.uk)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	02/06/2017		Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	version V1.1	29/06/2016	16/11/2016	No	Yes
Plain English results			30/06/2026	No	Yes